Roving Reporter Asks: What Is Your View on the Takeda “U-turn”?
April 29, 2026
IBTV speaks with industry leaders at the 2025 Meeting on the Mesa to unpack reactions to Takeda’s strategic shift.
False
Advertisement
Latest
This Week’s Biopharma News: Wave of Antibody Approvals
April 28, 2026
FDA expands Tzield, EU clears Dupixent, and Health Canada approves denosumab antibody biosimilars
4 min read
A Regulatory Roadmap for Early-Stage Biotech
By Tim Stonehouse
April 28, 2026
From first conversations with regulators to global market strategy, early decisions shape speed, risk, and long-term success
3 min read
This Week’s CGT News: Lilly’s $7B In Vivo CAR-T Bet
April 27, 2026
Lilly moves to acquire Kelonia, plus gene therapy for deafness approved
3 min read
Trends and Challenges in Nitrosamine Testing: Part Three – Building a Method
April 24, 2026
Following part two, which explored the analytical challenges involved in nitrosamine testing, our experts return to offer their top tips for building a method from scratch
4 min read
Roving Reporter Asks: What Was the Biggest Development in CGT of 2025?
April 22, 2026
IBTV speaks with industry leaders at the 2025 Meeting on the Mesa to uncover the year’s defining breakthroughs
10 min read
A Reliable Cold Chain is a Health Equity Issue
By Kuntal Baveja
April 21, 2026
Why temperature-controlled logistics is a critical but overlooked foundation of equitable access to medicines
4 min read
This Week’s Biopharma News: KRAS Breakthrough and ADC Momentum
April 21, 2026
Revolution’s KRAS breakthrough, strong ADC signals from GSK, and shifting regulatory and dealmaking dynamics define this week in biopharma
3 min read
This Week’s CGT News: New FDA Genome Editing Guidance
April 20, 2026
Our latest roundup highlights tighter FDA expectations for genome editing safety, advances in CRISPR precision and delivery, and continued momentum for off-the-shelf CAR-T
4 min read
The Secrets of the Gut
April 20, 2026
Going beyond the gut: why microbiome testing is the next big thing in drug development
3 min read
